Long-term outcomes from a prospective trial of stereotactic body radiotherapy for XXXX .

@entity1 @entity137 @entity263 @entity322 @entity1494 @entity5 @entity3885 @entity811 @entity1486
PURPOSE: Hypofractionated radiotherapy has an intrinsically different normal tissue and @entity5 radiobiology. The results of a prospective trial of stereotactic body radiotherapy (SBRT) for @entity263 with long-term @entity1 -reported @entity137 and @entity5 control rates are presented. METHODS AND MATERIALS: From 2003 through 2009, 67 @entity1 with clinically localized @entity263 were enrolled. Treatment consisted of 36.25 Gy in 5 fractions using SBRT with the CyberKnife as the delivery technology. No @entity1 received hormone therapy. @entity1 self-reported @entity1494 were graded on the Radiation Therapy Oncology Group scale (RTOG). RESULTS: Median follow-up was 2.7 years. There were no grade 4 @entity137 . Radiation Therapy Oncology Group Grade 3, 2, and 1 bladder @entity137 were seen in 3% (2 @entity1 ), 5% (3 @entity1 ), and 23% (13 @entity1 ) respectively. Dysuria exacerbated by urologic instrumentation accounted for both @entity1 with Grade 3 @entity137 . @entity322 , @entity3885 , or persistent @entity811 was not observed. Rectal Grade 3, 2, and 1 @entity137 were seen in 0, 2% (1 @entity1 ), and 12.5% (7 @entity1 ), respectively. Persistent rectal bleeding was not observed. Low-grade @entity137 were substantially less frequent with QOD vs. QD dose regimen (p = 0.001 for gastrointestinal and p = 0.007 for genitourinary). There were two @entity1486 (PSA), biopsy-proven failures with negative metastatic workup. Median PSA at follow-up was 0.5    0.72 ng/mL. The 4-year Kaplan-Meier PSA relapse-free survival was 94% (95% confidence interval, 85%-102%). CONCLUSION: Significant late @entity1494 from SBRT for @entity263 are infrequent. PSA relapse-free survival compares favorably with other definitive treatments. The current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for @entity263 .
